[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600943":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":57,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":23,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":23,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"A(68Ga-FAPI PET \u002F CT negative patients)","Group A (MRD-negative) will receive no intervention and enter treatment withdrawal with observational follow-up.",[12],"Diagnostic Test: 68Ga-FAPI PET \u002F CT",{"label":14,"type":6,"description":15,"interventionNames":16},"B(68Ga-FAPI PET \u002F CT positive patients)","Group B (68Ga-FAPI PET\u002FCT positive, indicating MRD-positive status). Group B (MRD-positive) patients will be randomized 1:1 into either the experimental subgroup B1 (continuing low-dose glucocorticoids with or without immunosuppressant maintenance therapy) or the control subgroup B2 (treatment withdrawal with observational follow-up).",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DIAGNOSTIC_TEST","68Ga-FAPI PET \u002F CT","IgG4-RD patients with clinical complete remission after hormone and immunosuppressive therapy and 18F-FDG PET \u002F CT negative were included. After enrollment, 68Ga-FAPI PET \u002F CT screening was performed.",[9,14],null,[25],{"name":26,"affiliation":5,"role":27},"Yaping LUO, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Yaping Luo, MD","CONTACT","86-010-69154716","luoyaping@live.com",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":23,"email":52},"Jiayue Li","86-010-69156874","xs@abscd.com",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Luo Yaping","Medical Doctor (M.D.), Chief Physician, Professor, Assistant Director",[58],{"name":5,"class":6},"100600943","a-study-on-the-effect-of-mrd-detected-by-fapi-pet--ct-on-the-recurrence-of-igg4-rd-100600943",false,"NCT07104058","A Study on the Effect of MRD Detected by FAPI PET \u002F CT on the Recurrence of IgG4-RD","A Prospective Study on the Effect of Minimal Residual Disease Detected by Fibroblast Activation Protein PET \u002F CT on the Recurrence of IgG4-related Disease","Inclusion Criteria:\n\n1. age 18-75 years old ;\n2. Meet the 2019 ACR \u002F EURLAR IgG4-RD diagnostic criteria ;\n3. The disease was stable for more than 1 year, and the clinical evaluation of the disease was complete remission \\* ;\n4. Glucocorticoid dosage ≤ prednisone 7.5mg \u002F d × 6 months or more, or combined with an immunosuppressive therapy ( mycophenolate mofetil ) Ester ≤ 1.0g \u002F d, leflunomide ≤ 20mg \u002F d, methotrexate ≤ 15mg \u002F w, azathioprine ≤ 100mg \u002F d, iguratimod ≤ 25mg Bid )\n\nExclusion Criteria:\n\n( 1 ) Combined with other connective tissue disease patients ( 2 ) patients with tumor ; ( 3 ) women during pregnancy or planning pregnancy ; ( 4 ) active infection, including HIV, HCV, HBV, TB, etc. ; ( 5 ) Severe irreversible organ damage ; ( 6 ) In the active stage of the disease, the IgG4-RD reaction index score of the single affected organ was 2 points ; ( 7 ) stable condition less than 1 year ; ( 8 ) patients who relapsed within 1 year of previous hormone reduction and withdrawal ; ( 9 ) Combination of two or more immunosuppressive agents.","ALL","18 Years","75 Years",{"count":70,"type":71},46,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study intends to use the new technology of fibroblast activation protein PET \u002F CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET \u002F CT are related to the recurrence of IgG4-RD in patients with IgG4-RD who have been clinically evaluated for complete remission after treatment.",[77],"IgG4-Related Diseases",[77,79],"FAPI PET\u002FCT","2025-08-03",{"date":82,"type":83},"2025-08-05","ACTUAL",{"date":85,"type":83},"2025-05-10",{"date":87,"type":71},"2027-12-01",{"name":55,"class":6},1]